OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr McCarthy on Neutrophil Activity in Multiple Myeloma

August 30th 2024

Philip McCarthy, MD, discusses a study of neutrophil gene signatures within focal lesions that are linked to progression-free survival in multiple myeloma.

Dr Olivares on the Functional Advantages of Focal Therapy in Prostate Cancer

August 30th 2024

Ruben Olivares, MD, discusses the functional advantages of using focal therapy over localized radiation in prostate cancer.

Dr Dizman on Future Efforts to Elucidate Benefit With CBM588 in First-Line RCC

August 30th 2024

Nazli Dizman, MD, discusses next steps planned for research with CBM588 in patients with renal cell carcinoma in the first line.

Dr Dasari on Salvage Treatment Considerations for Unresectable Metastatic CRC

August 30th 2024

Arvind N. Dasari, MD, MS, discusses later-line treatment considerations for patients with unresectable metastatic colorectal cancer.

Dr Li on Safety Data Derived From the CORE-001 Trial in BCG-Unresponsive NMIBC

August 30th 2024

Roger Li, MD, discusses safety data from the final analysis of the CORE-001 trial in BCG-unresponsive non–muscle-invasive bladder cancer.

Dr Li on Cretostimogene Grenadenorepvec Plus Pembrolizumab in BCG-Unresponsive NMIBC

August 29th 2024

Roger Li, MD, discusses the final analysis of the CORE-001 trial of cretostimogene grenadenorepvec plus pembrolizumab in BCG-unresponsive NMIBC with CIS.

Dr Tolaney on Standard Frontline Treatment Approaches in HER2+ Breast Cancer

August 29th 2024

Sara M. Tolaney, MD, MPH, discusses standard-of-care frontline treatment approaches for patients with HER2-positive breast cancer.

Dr Singhi on the Potential Benefit of the ADRIATIC Study Findings in LS-SCLC

August 29th 2024

Eric Kumar Singhi, MD, discusses unmet needs in the management of small cell lung cancer, highlighting how the ADRIATIC study addressed these needs.

Dr Grünwald on Tumor Burden Outcomes From the CLEAR Trial in Advanced RCC

August 29th 2024

Viktor Grünwald, MD, PhD, discusses differences in tumor burden between patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab vs sunitinib.

Dr Hantel on Eligibility Criteria Associated With Racial/Ethnic Disparities in Clinical Trial Enrollment in AML

August 29th 2024

Andrew Hantel, MD, discusses eligibility criteria associated with racial and ethnic disparities in clinical trial participation in acute myeloid leukemia.

Dr Krishnan on Maintenance Approaches in Transplant-Ineligible Multiple Myeloma

August 29th 2024

Amrita Krishnan, MD, discusses maintenance therapy for patients with transplant-ineligible, newly diagnosed multiple myeloma.

Dr Daver on the Evolution of Survivorship and Treatment Outcomes in AML

August 29th 2024

Naval G. Daver, MD, discusses the evolution of survivorship in patients with acute myeloid leukemia.

Dr Olivares on Considerations for Managing Prostate Cancer in the Community Setting

August 29th 2024

Ruben Olivares, MD, discusses considerations for managing prostate cancer in the community setting, particularly regarding early detection and screening.

Dr Banerjee on Various Dosing Schedules of Bispecific Antibodies in Myeloma

August 29th 2024

Rahul Banerjee, MD, FACP, discusses the ongoing investigation into different dosing schedules of bispecific antibodies in multiple myeloma.

Dr Vahdat on the Role of Copper Depletion in Reducing Metastatic Disease Risk in TNBC

August 28th 2024

Linda Vahdat, MD, MBA, discusses the role of copper depletion in reducing the risk of metastatic disease development in triple-negative breast cancer.

Dr Liao on the Value of Molecular Testing in Biliary Tract Carcinoma

August 28th 2024

Chih-Yi Liao, MD, discusses the value of molecular testing in biliary tract carcinoma.

Dr Strickler on the Significance of Fruquintinib for Patients With Refractory mCRC

August 28th 2024

John H. Strickler, MD, discusses the significance of fruquintinib for patients with metastatic colorectal cancer who have exhausted standard therapies.

Dr Shadman on the Impact of Early Dose Reduction on Real-World Outcomes With Ibrutinib in CLL/SLL

August 28th 2024

Mazyar Shadman, MD, MPH, discusses real-world outcomes following early dose adjustments of first-line ibrutinib in CLL/SLL.

Dr McGregor on the Investigation of Abemaciclib Monotherapy in ccRCC

August 28th 2024

Bradley McGregor, MD, discusses the rationale for investigating abemaciclib monotherapy in patients with clear cell renal cell carcinoma.

Dr Guerra on the Implications of a Study on Prostate Cancer Screening in Diverse Populations

August 28th 2024

Carmen Guerra, MD, MSCE, FACP, discusses the implications of research into the rates of prostate cancer screening in a population of diverse men.